Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Health Times.
Press releases published on May 21, 2025
Verano to Celebrate Grand Opening of Zen Leaf Enfield, Company’s Seventh Connecticut Dispensary, Throughout Memorial Day Weekend
GlobeNewswire
·
May 21, 2025
Zen Leaf Enfield, located at 98 Elm St., adjacent to Enfield Square Mall, joins the local business community ahead of the Mall’s $250 million transformative redevelopment to “Enfield Marketplace” Verano provided funds to the Thompsonville Fire Department …
Curium and NRG PALLAS extend collaboration in the supply of essential medical isotope to hospitals
GlobeNewswire
·
May 21, 2025
PETTEN, The Netherlands, May 21, 2025 (GLOBE NEWSWIRE) -- NRG PALLAS and Curium have extended their collaboration to produce molybdenum-99 through a new multi-year agreement. Molybdenum-99, which transforms into technetium-99, is a critical isotope used in …
EuroPCR 2025: Aktuelle Daten belegen: Die Ereignisraten nach drei Jahren sind beim DynamX® Bioadaptor von Elixir Medical anhaltend signifikant niedriger als bei medikamentenfreisetzenden Stents
GlobeNewswire
·
May 21, 2025
Paris, May 21, 2025 (GLOBE NEWSWIRE) -- – Anhaltende Dauerhaftigkeit des Behandlungseffekts bei signifikant niedrigeren TLF-Raten (2,7 % vs. 7,2 %, p = 0,030) bei DynamX® im Vergleich zu DES – – Signifikant niedrigere Herztodrate (0,5 % vs. 3,2 %, p = 0, …
EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical’s DynamX Bioadaptor Over Drug-Eluting Stent Through Three Years
GlobeNewswire
·
May 21, 2025
Paris, May 21, 2025 (GLOBE NEWSWIRE) -- —Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX® compared to DES— —Significantly lower rate of Cardiac Death (0.5% versus 3.2%, p=0.033) with …
EuroPCR 2025: Los datos más recientes demuestran que el bioadaptador DynamX® de Elixir Medical ofrece tasas significativamente menores de acontecimientos adversos a lo largo de tres años en comparación con el stent liberador de fármaco
GlobeNewswire
·
May 21, 2025
Paris, May 21, 2025 (GLOBE NEWSWIRE) -- —Durabilidad sostenida del efecto del tratamiento y tasas de fracaso de la lesión objetivo significativamente menores (2,7 % frente a 7,2 %, p=0,030) con DynamX® en comparación con SLF— —Tasa significativamente menor …
EuroPCR 2025 : Des données récentes démontrent une réduction durable et statistiquement significative des taux d’événements avec le bioadaptateur DynamX® d’Elixir Medical par rapport au stent à élution médicamenteuse (SEM) sur trois ans
GlobeNewswire
·
May 21, 2025
Paris, 21 mai 2025 (GLOBE NEWSWIRE) -- —Un effet thérapeutique durable avec des taux de TLF significativement inférieurs (2,7 % contre 7,2 %, p = 0,030) avec DynamX® par rapport au SEM— —Taux de décès cardiaque significativement inférieur (0,5 % contre 3,2 …
EuroPCR 2025: i dati più recenti dimostrano una riduzione duratura e significativa dei tassi di eventi fino a tre anni con il bioadattatore DynamX® di Elixir Medical rispetto allo stent a rilascio di farmaco
GlobeNewswire
·
May 21, 2025
Paris, May 21, 2025 (GLOBE NEWSWIRE) -- —Durata sostenuta dell’efficacia del trattamento con tassi di TLF significativamente inferiori (2,7% vs. 7,2%, p=0,030) con DynamX® rispetto al DES— —Tasso significativamente inferiore di morte cardiaca (0,5% vs. 3, …
EuroPCR 2025: Najnowsze dane potwierdzają trwały i istotnie niższy odsetek niepożądanych zdarzeń klinicznych przy zastosowaniu bioadaptatora DynamX® firmy Elixir Medical w porównaniu do stentu uwalniającego lek (DES) w okresie trzech lat
GlobeNewswire
·
May 21, 2025
Paris, May 21, 2025 (GLOBE NEWSWIRE) -- — Trwały efekt terapeutyczny z istotnie niższym współczynnikiem niepowodzeń leczenia zmiany docelowej (TLF) – 2,7% wobec 7,2% (p=0,030) dla DynamX® w porównaniu do DES — — Istotnie niższy współczynnik zgonów sercowo- …
tiakis Biotech AG Announces Appointment of ex-Actelion Executive Christoph Schmidt as New Supervisory Board Member
GlobeNewswire
·
May 21, 2025
- Successful track record in the commercialization of biopharmaceutical products as well as strategic advisory in orphan diseases Kiel, Germany, May 21, 2025 – tiakis Biotech AG, a clinical-stage biopharmaceutical company developing novel …
Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease
GlobeNewswire
·
May 21, 2025
Designation is based on the pivotal Phase 3 DRAGON trial interim analysis results demonstrating Tinlarebant’s efficacy and favorable safety profile Trial completion expected by Q4 2025 (including a three-month follow-up period) Tinlarebant has previously …
Juvenescence closes $76m first tranche of Series B-1 financing led by Abu Dhabi’s M42 alongside strategic partnership
GlobeNewswire
·
May 21, 2025
Juvenescence closes $76m first tranche of Series B-1 financing led by Abu Dhabi’s M42 alongside strategic partnership Close of $76m Series B-1 tranche follows recent announcement of groundbreaking strategic partnership with M42 to collaborate in drug …
ONWARD Medical Advances Brain-Computer Interface Leadership with Fourth and Fifth Successful BCI Implants
GlobeNewswire
·
May 21, 2025
Groundbreaking procedures extend ONWARD’s leadership in the rapidly emerging brain-computer interface (BCI) field ARC-BCI Therapy is designed to restore thought-driven movement after spinal cord injury and other movement disabilities ONWARD’s BCI …
Augustine Therapeutics appoints Rie Schultz Hansen, PhD as Chief Scientific Officer and establishes Copenhagen-based subsidiary
GlobeNewswire
·
May 21, 2025
Augustine Therapeutics appoints Rie Schultz Hansen, PhD as Chief Scientific Officer and establishes Copenhagen-based subsidiary New recruit expands senior team capabilities as the business progresses its lead HDAC6 inhibitor program, AGT-100216, into the …
SYNDEO Medical Announces ISO 13485 Certification, Expanding Regulatory Portfolio and Supporting Global Growth Strategy
GlobeNewswire
·
May 21, 2025
ZAVENTEM, Belgium, May 20, 2025 (GLOBE NEWSWIRE) -- SYNDEO Medical, a Belgian-based developer of interventional procedure solutions, is pleased to announce that it has received ISO 13485 certification for its quality management system. This internationally …